The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)
Public ClinicalTrials.gov record NCT03591354. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Extension Study of t:Slim X2 With Control-IQ Technology
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 3-month extension study (DCLP3 Extension) following a primary trial (DCLP3 or NCT03563313) to assess efficacy and safety of a closed loop system (t:slim X2 with Control-IQ Technology) in a large randomized controlled trial. Upon completion of the NIH 3-month extension study, subjects will be invited to participate in a continued use phase with Control-IQ Technology, funded by Tandem Diabetes Care, until the equipment has received FDA approval for commercial use.
Study identification
- NCT ID
- NCT03591354
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 164 participants
Conditions and interventions
Conditions
Interventions
- t:slim X2 with Control-IQ Technology & Dexcom G6 CGM Device
- t:slim X2 with Basal-IQ & Dexcom G6 CGM Device
Device
Eligibility (public fields only)
- Age range
- 14 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 16, 2019
- Primary completion
- Feb 27, 2020
- Completion
- Mar 8, 2020
- Last update posted
- Aug 30, 2022
2019 – 2020
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sansum Diabetes Research Institute | Santa Barbara | California | 93105 | — |
| Stanford University | Stanford | California | 94304 | — |
| Barbara Davis Center, University of Colorado | Aurora | Colorado | 80045 | — |
| Harvard University (Joslin Diabetes Center) | Boston | Massachusetts | 02215 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| University of Virginia Center for Diabetes Technology | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03591354, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2022 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03591354 live on ClinicalTrials.gov.